BioLineRx (NASDAQ:BLRX – Get Rating) posted its earnings results on Wednesday. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01), Zacks reports. During the same quarter in the previous year, the business earned ($0.10) EPS.
BioLineRx Price Performance
Shares of NASDAQ:BLRX traded down $0.15 during trading on Friday, reaching $1.40. The company had a trading volume of 363,120 shares, compared to its average volume of 405,769. The firm’s fifty day moving average is $1.12 and its 200 day moving average is $0.81. The firm has a market capitalization of $86.11 million, a PE ratio of -2.82 and a beta of 1.89. BioLineRx has a twelve month low of $0.55 and a twelve month high of $1.98. The company has a debt-to-equity ratio of 0.17, a quick ratio of 4.87 and a current ratio of 4.87.
Analyst Upgrades and Downgrades
A number of research analysts have issued reports on BLRX shares. StockNews.com started coverage on shares of BioLineRx in a research note on Thursday, May 18th. They set a “sell” rating for the company. HC Wainwright reissued a “buy” rating on shares of BioLineRx in a research note on Wednesday, March 22nd.
Institutional Trading of BioLineRx
BioLineRx Company Profile
BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. Its product pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is an immunotherapy treatment used for multiple solid tumors.
- Get a free copy of the StockNews.com research report on BioLineRx (BLRX)
- Big Lots Becomes A Stomach Churning Value Play
- The Melt-Up In Marvell Is On; But Don’t Chase It Higher
- Is Apple a Growth Stock or a Value Stock?
- Costco’s Earnings Call Reassure Economists, Recession Cancelled
- Hot Inflation, What It Means For The Summer Rally
Receive News & Ratings for BioLineRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx and related companies with MarketBeat.com's FREE daily email newsletter.